IMMUNIC, INC. (IMUX) Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Immunic, Inc. NASDAQ:IMUX Healthcare · Biotechnology
Mkt Cap $102.47M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
Immunic announced a virtual R&D Day focused on progressive multiple sclerosis, scheduled for November 5, 2026, at 12:30 pm ET.
Management plans to highlight the expansion opportunity for lead asset vidofludimus calcium (IMU-838) in progressive MS, including plans to initiate a Phase 3 progressive MS trial later in 2026.
The company also reiterated that top-line data from its Phase 3 relapsing MS trials are expected by the end of 2026; no new clinical or financial data were disclosed in this release.
• 3d ago AI analysis › Press Release ⚠ 3
Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Immunic presented four posters of new clinical, biomarker, and preclinical data for vidofludimus calcium (IMU-838) at the joint ACTRIMS-ECTRIMS meeting in Toronto.
Phase 2 CALLIPER open-label extension data showed durable disability-outcome trends with continued treatment, and post-hoc analyses using novel bidirectional endpoints showed patients 2.47x more likely to achieve confirmed disability improvement (p=0.037). Preclinical work suggested Nurr1-dependent neuroprotection beyond DHODH inhibition.
Importantly, the CALLIPER primary endpoint (percent brain volume change) was not met -- these are exploratory and post-hoc findings.
The pivotal readout remains the fully enrolled Phase 3 ENSURE trials in relapsing MS, with top-line data expected by year-end 2026, plus a planned Phase 3 start in progressive MS later in 2026.
• 11d ago AI analysis › Press Release
Immunic Appoints Jaa Roberson as Chief People Officer
Immunic appointed Jaa Roberson as Chief People Officer, a newly created executive role, effective immediately.
Roberson brings two decades of biopharma HR experience, most recently scaling Day One Biopharmaceuticals from 37 to 200 employees through its clinical-to-commercial transition. She will report directly to CEO Erik Lundgren and help build the organization ahead of potential commercialization.
The hire signals Immunic's preparation for the pivotal Phase 3 ENSURE read-out of vidofludimus calcium in relapsing MS, expected by the end of 2026, and a potential shift to a fully integrated commercial company.
Roberson received an inducement grant of options to purchase 190,000 shares under NASDAQ Rule 5635(c)(4), vesting over roughly four years.
• 13d ago AI analysis › Press Release
Immunic Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunic granted inducement equity awards covering 12,900 shares to three new employees on October 1, 2026, under its 2026 Inducement Equity Compensation Plan.
The grants comply with Nasdaq Listing Rule 5635(c)(4) and vest with 25% on the first anniversary of hire, then monthly over 36 installments.
The share count is negligible; the only mildly notable context is the company's reaffirmation that Phase 3 relapsing MS top-line data for vidofludimus calcium is expected by end of 2026.
• 19d ago AI analysis › Press Release ⚠ 2
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Immunic announced four accepted abstracts on vidofludimus calcium for presentation at MSToronto2026, the joint ACTRIMS-ECTRIMS meeting, October 21-23, 2026, in Toronto.
New Phase 2 CALLIPER open-label extension data show disability outcomes favoring continuous treatment maintained through extension Week 48 with low discontinuation, plus preclinical evidence that Nurr1 is required for the drug's neuronal-survival effect.
The company's Phase 3 relapsing MS program remains on track for top-line data by end of 2026, making this a supportive precursor rather than a pivotal readout.
• 25d ago AI analysis › Press Release
Immunic Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunic granted inducement equity awards covering an aggregate 196,350 shares to seven new employees between September 14 and September 28, 2026.
The grants were made under the 2026 Inducement Equity Compensation Plan pursuant to Nasdaq Listing Rule 5635(c)(4), vesting 25% on the first anniversary of hire with the remainder vesting monthly over 36 months.
The release is an administrative disclosure with no bearing on the company's lead Phase 3 program, vidofludimus calcium, whose top-line data in relapsing multiple sclerosis is expected by the end of 2026.
• 1mo ago AI analysis › Press Release
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
Immunic will host a virtual R&D day focused on relapsing multiple sclerosis on Wednesday, September 9, 2026, from 11:00 am to 12:30 pm ET via Zoom.
Management — including CEO Erik Lundgren and CMO Michael Panzara — will be joined by MS key opinion leaders Amit Bar-Or of the University of Pennsylvania and Stephen Krieger of Mount Sinai to discuss the lead asset vidofludimus calcium (IMU-838), an oral small molecule combining Nurr1 activation with selective DHODH inhibition aimed at both neurodegenerative and inflammatory drivers of MS.
The event is scheduled ahead of top-line data from the Phase 3 ENSURE trials in relapsing MS, expected by the end of 2026, with initiation of an additional Phase 3 trial in progressive MS expected later in 2026.
• 1mo ago AI analysis › Press Release
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
Immunic appointed Chitrang Davé as Chief Data and Digital Officer, a newly created C-suite role focused on building a data and digital ecosystem for commercialization.
Mr. Davé will support the preparation of the data package for the potential NDA submission of vidofludimus calcium (IMU-838), with top-line Phase 3 data expected by year-end.
The Compensation Committee granted him an inducement option to purchase 120,000 shares, vesting over four years.
• 2mo ago AI analysis › Press Release
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Immunic ended the second quarter with $155.1 million in cash, sufficient to fund operations into late 2027, following a successful private placement earlier this year.
The company strengthened its leadership team by appointing Erik Lundgren as CEO and Michael Panzara as CMO, while Michael Bonney became Chair of the Board, bringing extensive experience in MS drug launches at Genentech, Biogen, and Sanofi.
Phase 3 ENSURE trials for vidofludimus calcium in relapsing MS remain on track, with top-line data expected by the end of 2026 and a planned NDA submission in mid-2027 pending positive results.
• 2mo ago AI analysis › Press Release
Immunic Appoints Elena Ridloff to Board of Directors
Immunic appointed Elena Ridloff, CFA, to its Board of Directors, effective August 6, 2026, bringing over two decades of financial strategy and capital markets expertise to the biopharmaceutical company.
Ms. Ridloff currently serves as CFO of Sionna Therapeutics and previously led finance at ACADIA Pharmaceuticals, where she played a key role in raising $600 million in capital.
The announcement comes as Immunic prepares for top-line Phase 3 data readouts for its lead asset vidofludimus calcium in relapsing multiple sclerosis, expected by the end of 2026.
• 2mo ago AI analysis › Press Release
Immunic to Participate in Investor Conferences in July
Immunic announced participation in three investor conferences in July, including the Leerink Partners Therapeutics Forum, B. Riley Securities Mind, Muscle & Vision Summit, and LifeSci Capital SF Biotech Forum.
Executive team members, including CEO Erik Lundgren and CMO Michael Panzara, will hold one-on-one meetings and a fireside chat to discuss the company's pipeline.
The release serves as a standard calendar update with no new operational or financial disclosures.
• 3mo ago AI analysis › Press Release
Immunic to Participate in Investor, Industry and Scientific Conferences in June
Immunic announced its management team will participate in four investor, industry, and scientific conferences in June 2026.
CEO Erik Lundgren and COO Jason Tardio will hold a fireside chat at the H.C. Wainwright Neuro Perspectives Expert Summit on June 15-16.
The company will also have a presence at the BIO International Convention, the EFMC-ACSMEDI Medicinal Chemistry Frontiers Symposium, and the European Academy of Neurology Congress.
No new clinical data or financial results were released; this is a standard calendar update for investor relations.
• 4mo ago AI analysis › Press Release
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic presented three posters at the CMSC Annual Meeting highlighting additional data from its Phase 2 CALLIPER trial for vidofludimus calcium in progressive multiple sclerosis.
A late-breaking poster introduced a novel 'Confirmed Disability Change' endpoint, showing favorable effects for vidofludimus calcium versus placebo across multiple statistical models, suggesting potential neuroprotective benefits.
Safety data from 467 patients showed treatment-emergent adverse events were comparable between drug (69.4%) and placebo (68.5%), with no signal of worsening depressive thoughts or liver toxicity.
• 5mo ago AI analysis › Press Release
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
Immunic appointed Erik Lundgren as Chief Executive Officer, effective May 22, 2026, with employment beginning June 1, 2026. Lundgren succeeds Daniel Vitt, who will remain on the board and oversee scientific strategy.
Lundgren brings nearly two decades of biopharma experience, including a key role in launching Ocrevus at Genentech/Roche. He will lead Immunic through the pivotal Phase 3 ENSURE trial readout for vidofludimus calcium in relapsing multiple sclerosis, expected by year-end 2026.
The move signals Immunic's transition toward a commercial-stage company, with Lundgren tasked with preparing for potential NDA filing and commercialization. He received an inducement grant of 1 million stock options.
• 5mo ago AI analysis › Press Release ● Major
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
prnewswire.com • 5mo ago Press Release ● Major
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
prnewswire.com • 5mo ago Press Release
Immunic to Participate in Investor and Medical Conferences in May
Immunic announced it will attend the Bio€quity Europe conference in Prague and the CMSC Annual Meeting in Charlotte during May.
Management plans to host one-on-one meetings and present three posters, including late-breaking statistical analyses and Phase 2 CALLIPER trial data for vidofludimus calcium.
The company's lead asset, vidofludimus calcium, remains in Phase 3 development for relapsing multiple sclerosis with top-line data expected by the end of 2026.
• 6mo ago AI analysis › Press Release
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
Immunic appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer, effective April 24, 2026, succeeding co-founder Andreas Muehler who will remain as a consultant.
Dr. Panzara brings over 25 years of experience in neurology, having overseen global regulatory approvals for key MS therapies like LEMTRADA and AUBAGIO during his tenure at Sanofi Genzyme.
The strategic hire comes months ahead of the expected top-line data from the Phase 3 ENSURE trials for vidofludimus calcium in relapsing MS, positioning the company for a potential commercial transition.
• 6mo ago AI analysis › Press Release
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.
prnewswire.com • 6mo ago Press Release ⚠ 1
Immunic, Inc. Announces 1-for-10 Reverse Stock Split
Immunic announced a 1-for-10 reverse stock split effective April 27, 2026, reducing outstanding shares from approximately 136 million to 13.6 million.
The board approved the specific 1-for-10 ratio within the range approved by stockholders; the action is primarily intended to meet contractual obligations under a securities purchase agreement from February 2026.
Trading will continue on the Nasdaq Capital Market under the symbol IMUX on a split-adjusted basis with a new CUSIP number.
• 6mo ago AI analysis › Press Release ● Major
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
prnewswire.com • 7mo ago Press Release
Immunic to Participate in Investor Conferences in March
prnewswire.com • 7mo ago Press Release ● Major
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
prnewswire.com • 8mo ago Press Release ● Critical
Immunic Announces Closing of Oversubscribed Private Placement Financing
prnewswire.com • 8mo ago Press Release ● Critical
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
prnewswire.com • 8mo ago Press Release ● Major
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
prnewswire.com • 8mo ago Press Release ● Major
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
prnewswire.com • 9mo ago 
